US Federal 2025-2026 Regular Session

US Federal House Bill HB7407

Introduced
2/5/26  

Caption

Prohibiting Tianeptine and Other Dangerous Products Act of 2026

Impact

If passed, HB7407 will enhance federal regulatory powers concerning dietary supplements, specifically targeting products that do not meet established safety criteria. This bill aims to protect consumers from substandard and potentially harmful dietary products. By introducing new definitions and prohibitions, it will also empower regulatory bodies to take action against businesses that violate these standards, thereby reinforcing consumer safety and public health efforts.

Summary

House Bill 7407, titled the 'Prohibiting Tianeptine and Other Dangerous Products Act of 2026', aims to amend the Federal Food, Drug, and Cosmetic Act to introduce new prohibited acts related to dietary supplements. The primary focus of the bill is to address the growing public health concerns surrounding certain dietary supplements, particularly those that may pose significant risks to consumers. The bill seeks to impose stricter regulations on the introduction and distribution of dietary products that do not align with federal definitions and safety standards.

Conclusion

Overall, HB7407 represents a significant legislative effort to address safety concerns in the dietary supplement market. By establishing clearer regulations and prohibited acts, it aims to ensure consumer protection while balancing the interests of public health and the dietary supplement industry. Stakeholders in this sector will need to closely monitor the bill's progress and prepare for potential changes in compliance and market dynamics.

Contention

A notable point of contention surrounding this bill is the debate over the regulatory scope and the impact it might have on businesses within the dietary supplement industry. Proponents argue that the bill is essential for safeguarding public health and curbing the distribution of dangerous products like Tianeptine, which have been linked to adverse health outcomes. However, critics may raise concerns about the potential overreach of federal regulations that could restrict access to beneficial supplements and disrupt the market for small businesses dedicated to health and wellness.

Companion Bills

US SB3797

Same As Prohibiting Tianeptine and Other Dangerous Products Act of 2026

Previously Filed As

US SB3797

Prohibiting Tianeptine and Other Dangerous Products Act of 2026

US AB634

Tianeptine.

US S322

Establishes tianeptine as Schedule II controlled dangerous substance.

US HB1720

TIANEPTINE PROHIBITION ACT

US S670

Requires producers of plastic packaging and certain other plastic products to reduce quantity of plastic sold; restricts additional substances under "Toxic Packaging Reduction Act."

US SB3677

Dietary Supplement Listing Act of 2026

US A3725

Requires producers of plastic packaging and certain other plastic products to reduce quantity of plastic sold; restricts additional substances under "Toxic Packaging Reduction Act."

US HB1282

Tobacco Products, Other Tobacco Products, and Electronic Smoking Devices - Advertising to Minors - Prohibition

US HB8385

Food Labeling Modernization Act of 2026

US HB8370

Dietary Supplement Listing Act of 2026

Similar Bills

No similar bills found.